NovoCure (NASDAQ:NVCR) had its "neutral" rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Why NovoCure Is Failing To Disrupt NSCLC [Seeking Alpha]
NovoCure (NASDAQ:NVCR) had its price target lowered by analysts at HC Wainwright from $42.00 to $39.00. They now have a "buy" rating on the stock.
Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
NovoCure (NASDAQ:NVCR) was given a new $20.00 price target on by analysts at Evercore ISI.